Leonardo DRS, Inc.
DRSLeonardo DRS, Inc.'s earnings have outrun its stock. EPS grew +28.7% in a year against a +8.6% price move.
Biggest watch item: the price is already 14 weeks into its uptrend — timing risk, not thesis risk.
The price is in a confirmed uptrend (14 weeks in). Underneath, the last four quarters read improving — profit +28.6% year on year, and 90% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Leonardo DRS, Inc. trades at $45.3, in a confirmed uptrend and 14 weeks into that stage. That is +9.2% against its own 200-day average. It sits at 78% of a 52-week range of $33 to $49. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 3 straight weeks.
Today the stock is in a confirmed uptrend — week 14 of stage 2. At $45.3 it trades +9.2% versus its 200-day average and sits at 78% of its 52-week range ($33–$49).
Against the market, two honest reads. Cumulative: over the last 3.7 years the stock moved +366% while the S&P 500 moved +90% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 3 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Leonardo DRS, Inc. trades at 38.0× P/E, against too little history to rank. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 38.0× is against too little history to rank. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +28.7% against a +8.6% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 3y, of the +38.4%/yr price move, ~−15.8%/yr came from earnings growth and ~+54.2 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Leonardo DRS, Inc. reads as mixed on its fundamental arc. Mixed — the growth curves are steadily positive, but ROCE at 11.1% is below the 15% bar this page requires to call it Consistent. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +13.0% | +10.7% | — | — |
| Profit | +21.9% | −1.7% | — | — |
| EPS | +28.7% | −18.2% | — | — |
| Stock price | +8.6% | +38.4% | — | — |
4-Factor Sector Score
55.2/100 — rank 9 of 30 in Aerospace & Defense · 56% evidence confidence
Leonardo DRS, Inc. scores 55.2 out of 100 against the 30 companies it is compared with in Aerospace & Defense, ranking 9. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 20.7 + 12.4 + 10.5 + 11.6 = 55.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Leonardo DRS, Inc. reported $0.8 B of revenue in the Mar 26 quarter, +6.3% year on year. That is the 11th straight quarter of year-on-year growth. Over 4 years it has compounded at 6.1% a year. The last full year, FY25, came in at $3.6 B. The last four reported quarters add to $3.7 B.
FY25 revenue came in at $3.6 B (+13.0% on the year), capping 4 years at 6.1% compound. The latest quarter (Mar 26) printed $0.8 B, +6.3% year on year — the 11th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +10.9% growth against the decade's 6.1% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +10.8% over the last 4 quarters against +12.0%/yr over the last 8 — stabilising; TTM profit +65.4% vs +50.4%/yr — accelerating.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Leonardo DRS, Inc.'s operating margin is 9.4% in the Mar 26 quarter, +1.9 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 8.1% to 20.8%. The current quarter sits inside that band.
The latest quarter's operating margin is 9.4%, +1.9 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 8.1%–20.8%.
Why the margin moved: operating margin went +1.9 pp year on year while gross margin went +2.2 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Leonardo DRS, Inc. earned $0.1 B of net profit in the Mar 26 quarter, +28.6% year on year. It is the 7th consecutive quarter of growth. Full-year FY25 profit was $0.4 B. The 4-year compound rate is 27.0%. That is 10.6% of the quarter's revenue. The same quarter a year earlier earned $0.1 B.
Mar 26 profit was $0.1 B, +28.6% year on year — the 7th consecutive quarter of growth. On the full year, FY25 printed $0.4 B (+21.9%), and the 4-year compound rate is 27.0%.
Why profit moved: revenue contributed +6.3% and the margin +1.9 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +53.7% vs revenue +10.9%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 90% of Leonardo DRS, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.4 B of operating cash against $0.4 B of profit. After $0.1 B of capital spending, $0.2 B was left as free cash.
FY25: operating cash of $0.4 B against reported profit of $0.4 B, leaving free cash of $0.2 B after $0.1 B of capital spending. Across the last 3 fiscal years the conversion rate is 90% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Leonardo DRS, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Leonardo DRS, Inc. earns a ROE of 14% in FY25. That is up from a trough of 9% in FY21. Return on invested capital clears the cost of that capital by +6.9 percentage points, so growth here adds value rather than only size. The wiring behind it is 10.7% net margin on 0.81× asset turns.
FY25 ROE is 14%, recovered from a FY21 trough of 9% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 10.7% net margin × 0.81× asset turns × 1.64× balance-sheet leverage ≈ 14.2% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 12.0% − 5.1% = a +6.9 pp spread. The 5.1% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Leonardo DRS, Inc. paid $0.36 per share over the last four reported quarters. The most recent declaration was $0.09 for Mar 26. Against the current price of $45.3 that is a trailing yield of 0.80%, measured on dividends already paid rather than on a forecast.
Leonardo DRS, Inc. paid $0.36 per share across the last four reported quarters, most recently $0.09 for Mar 26. Against the current price of $45.3 the trailing twelve months work out to 0.80% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Leonardo DRS, Inc. carries total debt of $0.1 B against shareholder equity of $2.8 B as of Jun 26, a debt-to-equity of 0.05 — effectively unlevered. On the annual view that ratio went from 0.30 in FY20 to 0.13 in FY25. The returns elsewhere on this page are therefore earned rather than borrowed.
Jun 26: total debt of $0.1 B against shareholder equity of $2.8 B — a debt-to-equity of 0.05. On the annual view, debt-to-equity went from 0.30 (FY20) to 0.13 (FY25). The returns on this page are earned, not borrowed.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
3.8% of Leonardo DRS, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 2.3 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 3.8% of the float is sold short, and at typical trading volumes it would take about 2.3 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Leonardo DRS, Inc.: the Z-score reads 5.55. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 5.55 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 5.55.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1HEICO CorporationHEI | 67.7/100Favorable setup81% evidence | BREAKING OUT | 24.4/35 Revenue 18.8% · PAT 30.2% · OPM change 2.9 pp 83% evidence | 15.5/25 ROCE 4.3% · OPM 25.5% 76% evidence | 10.5/20 P/E 48.2× · PEG 1.56 65% evidence | 17.3/20 RS sector 5% · RS bench 3.6% · 1Y 17.3%8 of 12 weeks ahead 100% evidence |
| Exact sum: 24.4 + 15.5 + 10.5 + 17.3 = 67.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Howmet Aerospace Inc.HWM | 65.9/100Favorable setup66% evidence | TURNING | 22.6/35 Revenue 14.2% · PAT 38.9% · OPM change 7.2 pp 53% evidence | 15.9/25 ROCE 7.5% · OPM 32.6% 57% evidence | 11.2/20 P/E 53.5× · PEG 1.32 65% evidence | 16.2/20 RS sector 16.2% · RS bench 13.9% · 1Y 59.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 22.6 + 15.9 + 11.2 + 16.2 = 65.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Elbit Systems Ltd.ESLT | 59.7/100Mixed-positive evidence66% evidence | TURNING | 20.6/35 Revenue 14.8% · PAT 66.9% · OPM change 1.5 pp 53% evidence | 12.3/25 ROCE 3.1% · OPM 9.4% 57% evidence | 11.6/20 P/E 68.8× · PEG 1.21 65% evidence | 15.2/20 RS sector 16.5% · RS bench 13.3% · 1Y 89%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20.6 + 12.3 + 11.6 + 15.2 = 59.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Lockheed Martin CorporationLMT | 59.3/100Thin evidence · provisional56% evidence | TURNING | 19.6/35 Revenue — · PAT — · OPM change -1.8 pp 39% evidence | 15.2/25 ROCE 6.8% · OPM 11.4% 76% evidence | 11.1/20 P/E 18.7× · PEG — 15% evidence | 13.4/20 RS sector 1.2% · RS bench -1.1% · 1Y 38.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 19.6 + 15.2 + 11.1 + 13.4 = 59.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Hexcel CorporationHXL | 58.7/100Thin evidence · provisional56% evidence | FADING | 21.0/35 Revenue — · PAT — · OPM change 1.8 pp 39% evidence | 11.4/25 ROCE 2.9% · OPM 11.5% 76% evidence | 9.8/20 P/E 50.3× · PEG — 15% evidence | 16.5/20 RS sector 17.4% · RS bench 15.2% · 1Y 72.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 21 + 11.4 + 9.8 + 16.5 = 58.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6RTX CorporationRTX | 58.2/100Thin evidence · provisional56% evidence | TURNING | 19.1/35 Revenue — · PAT — · OPM change 1.6 pp 39% evidence | 10.6/25 ROCE 2.5% · OPM 11.6% 76% evidence | 10.8/20 P/E 33.4× · PEG — 15% evidence | 17.7/20 RS sector 8.6% · RS bench 6.5% · 1Y 40.7%3 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 10.6 + 10.8 + 17.7 = 58.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7GE AerospaceGE | 57.7/100Mixed-positive evidence81% evidence | BREAKING OUT | 18.8/35 Revenue 21.7% · PAT 18.8% · OPM change 0.3 pp 83% evidence | 11.8/25 ROCE 2.9% · OPM 18.9% 76% evidence | 8.6/20 P/E 43.9× · PEG 2.09 65% evidence | 18.5/20 RS sector 10.7% · RS bench 9% · 1Y 37.2%8 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 11.8 + 8.6 + 18.5 = 57.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Woodward, Inc.WWD | 56.9/100Thin evidence · provisional56% evidence | ASLEEP | 20.5/35 Revenue — · PAT — · OPM change 1.2 pp 39% evidence | 15.1/25 ROCE 4.9% · OPM 14.7% 76% evidence | 9.7/20 P/E 50.5× · PEG — 15% evidence | 11.6/20 RS sector 4.5% · RS bench 2.1% · 1Y 50.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 20.5 + 15.1 + 9.7 + 11.6 = 56.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Leonardo DRS, Inc.this pageDRS | 55.2/100Thin evidence · provisional56% evidence | TURNING | 20.7/35 Revenue — · PAT — · OPM change 1.7 pp 39% evidence | 12.4/25 ROCE 3.3% · OPM 9.1% 76% evidence | 10.5/20 P/E 35.9× · PEG — 15% evidence | 11.6/20 RS sector -0.5% · RS bench -2.1% · 1Y 9.1%2 of 12 weeks ahead 100% evidence |
| Exact sum: 20.7 + 12.4 + 10.5 + 11.6 = 55.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10General Dynamics CorporationGD | 54.9/100Thin evidence · provisional56% evidence | BREAKING OUT | 17.3/35 Revenue — · PAT — · OPM change 0.5 pp 39% evidence | 13.1/25 ROCE 3.7% · OPM 10.5% 76% evidence | 11.0/20 P/E 22.8× · PEG — 15% evidence | 13.5/20 RS sector 1.5% · RS bench -0.1% · 1Y 22.8%3 of 12 weeks ahead 100% evidence |
| Exact sum: 17.3 + 13.1 + 11 + 13.5 = 54.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Curtiss-Wright CorporationCW | 54.2/100Mixed-positive evidence66% evidence | ASLEEP | 18.8/35 Revenue 12.2% · PAT 19.1% · OPM change 1.5 pp 53% evidence | 14.1/25 ROCE 4% · OPM 17.5% 57% evidence | 7.3/20 P/E 49.9× · PEG 2.33 65% evidence | 14.0/20 RS sector 9.1% · RS bench 6.8% · 1Y 60.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 14.1 + 7.3 + 14 = 54.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Embraer S.A.EMBJ | 53.0/100Mixed-positive evidence66% evidence | TURNING | 16.3/35 Revenue 20% · PAT -22.2% · OPM change 1 pp 53% evidence | 7.9/25 ROCE 1.1% · OPM 5.6% 57% evidence | 14.3/20 P/E 54.9× · PEG 0.51 65% evidence | 14.5/20 RS sector 1.9% · RS bench 0.2% · 1Y 20.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 16.3 + 7.9 + 14.3 + 14.5 = 53 · Decision use: Price leads the evidence: RS versus the benchmark is 0.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 13StandardAero, Inc.SARO | 52.4/100Thin evidence · provisional56% evidence | TURNING | 18.3/35 Revenue 15% · PAT 100% · OPM change -0.2 pp 53% evidence | 9.5/25 ROCE 2.8% · OPM 8.8% 57% evidence | 10.9/20 P/E 29.4× · PEG — 15% evidence | 13.7/20 RS sector 0.7% · RS bench -1% · 1Y 11.3%3 of 12 weeks ahead 100% evidence |
| Exact sum: 18.3 + 9.5 + 10.9 + 13.7 = 52.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Axon Enterprise, Inc.AXON | 48.0/100Thin evidence · provisional56% evidence | BREAKING OUT | 19.3/35 Revenue 34% · PAT -37.8% · OPM change 5.1 pp 53% evidence | 8.1/25 ROCE 0.6% · OPM 3.6% 57% evidence | 8.6/20 P/E 170.6× · PEG — 15% evidence | 12.0/20 RS sector -1.7% · RS bench -2.1% · 1Y -27.9%6 of 12 weeks ahead 100% evidence |
| Exact sum: 19.3 + 8.1 + 8.6 + 12 = 48 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15TransDigm Group IncorporatedTDG | 44.8/100Mixed-negative evidence66% evidence | TURNING | 16.2/35 Revenue 13.3% · PAT 9.6% · OPM change 0.2 pp 53% evidence | 15.6/25 ROCE 5.5% · OPM 46.3% 57% evidence | 5.7/20 P/E 35.6× · PEG 4.36 65% evidence | 7.3/20 RS sector -10.2% · RS bench -11.3% · 1Y -8.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 15.6 + 5.7 + 7.3 = 44.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Northrop Grumman CorporationNOC | 44.8/100Thin evidence · provisional56% evidence | BASING | 17.4/35 Revenue — · PAT — · OPM change 3.9 pp 39% evidence | 11.2/25 ROCE 3% · OPM 10% 76% evidence | 11.5/20 P/E 16.2× · PEG — 15% evidence | 4.7/20 RS sector -16.6% · RS bench -18.2% · 1Y -5.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.4 + 11.2 + 11.5 + 4.7 = 44.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Huntington Ingalls Industries, Inc.HII | 42.5/100Thin evidence · provisional56% evidence | ASLEEP | 16.5/35 Revenue — · PAT — · OPM change -0.9 pp 39% evidence | 9.5/25 ROCE 2.2% · OPM 5% 76% evidence | 11.4/20 P/E 16.7× · PEG — 15% evidence | 5.1/20 RS sector -11.3% · RS bench -13.5% · 1Y 22.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 9.5 + 11.4 + 5.1 = 42.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18CAE Inc.CAE | 42.3/100Mixed-negative evidence66% evidence | BASING | 10.5/35 Revenue 4.4% · PAT -22.4% · OPM change -7.6 pp 53% evidence | 10.8/25 ROCE 2% · OPM 12.9% 57% evidence | 14.8/20 P/E 37.3× · PEG 0.68 65% evidence | 6.2/20 RS sector -11.8% · RS bench -13.2% · 1Y -6.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 10.5 + 10.8 + 14.8 + 6.2 = 42.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 19Textron Inc.TXT | 41.5/100Thin evidence · provisional56% evidence | BASING | 15.6/35 Revenue — · PAT — · OPM change -0.8 pp 39% evidence | 9.4/25 ROCE 2% · OPM 6.3% 76% evidence | 11.3/20 P/E 17.4× · PEG — 15% evidence | 5.2/20 RS sector -7.9% · RS bench -9.5% · 1Y 15.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 15.6 + 9.4 + 11.3 + 5.2 = 41.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20The Boeing CompanyBA | 39.9/100Thin evidence · provisional56% evidence | BASING | 16.4/35 Revenue — · PAT — · OPM change -0.4 pp 39% evidence | 4.6/25 ROCE 0.3% · OPM 2% 76% evidence | 9.0/20 P/E 93.7× · PEG — 15% evidence | 9.9/20 RS sector -1.6% · RS bench -3.1% · 1Y 3.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.4 + 4.6 + 9 + 9.9 = 39.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21FTAI Aviation Ltd.FTAI | 39.8/100Thin evidence · provisional56% evidence | ASLEEP | 12.5/35 Revenue — · PAT — · OPM change -9.6 pp 39% evidence | 14.3/25 ROCE 5% · OPM 20.5% 76% evidence | 9.2/20 P/E 58.8× · PEG — 15% evidence | 3.8/20 RS sector -5.3% · RS bench -7.9% · 1Y 63.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12.5 + 14.3 + 9.2 + 3.8 = 39.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22L3Harris Technologies, Inc.LHX | 39.7/100Thin evidence · provisional53% evidence | BASING | 17.9/35 Revenue — · PAT — · OPM change 1.2 pp 32% evidence | 10.3/25 ROCE 1.9% · OPM 11.4% 76% evidence | 8.9/20 P/E 96× · PEG — 15% evidence | 2.6/20 RS sector -15.5% · RS bench -17.3% · 1Y 5.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 10.3 + 8.9 + 2.6 = 39.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23AeroVironment, Inc.AVAV | 37.3/100Mixed-negative evidence71% evidence | BASING | 17.6/35 Revenue 100% · PAT -702.3% · OPM change 3.9 pp 83% evidence | 6.4/25 ROCE 1.8% · OPM 8.9% 76% evidence | 8.7/20 P/E 97.8× · PEG — 15% evidence | 4.6/20 RS sector -36.8% · RS bench -37.6% · 1Y -31.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 6.4 + 8.7 + 4.6 = 37.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24BWX Technologies, Inc.BWXT | 34.2/100Adverse evidence66% evidence | BASING | 16.3/35 Revenue 21.4% · PAT 19% · OPM change -1.8 pp 53% evidence | 11.4/25 ROCE 2.7% · OPM 9.9% 57% evidence | 5.3/20 P/E 54.7× · PEG 2.86 65% evidence | 1.2/20 RS sector -18% · RS bench -19.5% · 1Y -3.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.3 + 11.4 + 5.3 + 1.2 = 34.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Kratos Defense & Security Solutions, Inc.KTOS | 33.9/100Thin evidence · provisional56% evidence | BASING | 18.0/35 Revenue 21.9% · PAT 50% · OPM change -0.9 pp 53% evidence | 6.6/25 ROCE 0.2% · OPM 1.3% 57% evidence | 8.5/20 P/E 423.2× · PEG — 15% evidence | 0.8/20 RS sector -36.5% · RS bench -37.9% · 1Y -18.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 6.6 + 8.5 + 0.8 = 33.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Planet Labs PBCPL | 30.2/100Adverse evidence61% evidence | ASLEEP | 13.8/35 Revenue 34% · PAT — · OPM change -2.7 pp 62% evidence | 3.4/25 ROCE -4.8% · OPM -37.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.0/20 RS sector -6.5% · RS bench -9.9% · 1Y 256.7%4 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 3.4 + 10 + 3 = 30.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Honeywell Aerospace Inc.HONA | 55.0/100Thin evidence · provisional18% evidence | 17.7/35 Revenue — · PAT — · OPM change -4.3 pp 10% evidence | 17.3/25 ROCE 14.4% · OPM 20.2% 57% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 17.7 + 17.3 + 10 + 10 = 55 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Moog Inc.MOG-B | 54.0/100Thin evidence · provisional33% evidence | BREAKING OUT | 19.6/35 Revenue — · PAT — · OPM change 1 pp 32% evidence | 14.0/25 ROCE 4.4% · OPM 10.8% 76% evidence | 10.4/20 P/E 36.1× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y 101.5%8 of 11 weeks ahead 0% evidence |
| Exact sum: 19.6 + 14 + 10.4 + 10 = 54 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29Rocket Lab CorporationRKLB | 42.4/100Thin evidence · provisional48% evidence | FADING | 22.4/35 Revenue 45.7% · PAT — · OPM change 20.4 pp 40% evidence | 6.0/25 ROCE -3.4% · OPM -27.9% 57% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.0/20 RS sector -5.1% · RS bench -7.4% · 1Y 66.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 22.4 + 6 + 10 + 4 = 42.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30Space Exploration Technologies Corp.SPCX | 41.7/100Thin evidence · provisional18% evidence | 16.3/35 Revenue — · PAT — · OPM change -42.1 pp 10% evidence | 5.4/25 ROCE -5% · OPM -41.4% 57% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 16.3 + 5.4 + 10 + 10 = 41.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Leonardo DRS, Inc.'s stock price today?
Leonardo DRS, Inc. trades at $45.3, +8.6% over the past year. The company is valued at $12.0 B. The stock sits at 78% of its 52-week range of $33–$49, +9.2% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 14 weeks in. — as of 5 August 2026.
What were Leonardo DRS, Inc.'s latest quarterly results?
Leonardo DRS, Inc. reported revenue of $0.8 B and net profit of $0.1 B for the Mar 26 quarter. Revenue rose 6.3% and profit rose 28.6% year on year. Earnings per share were $0.23. The operating margin was 9.4%, 1.9 pp higher than a year earlier. — as of 5 August 2026.
What is Leonardo DRS, Inc.'s revenue?
Leonardo DRS, Inc. reported revenue of $0.8 B in the Mar 26 quarter, +6.3% year on year. For the full FY25 fiscal year, revenue was $3.6 B (+13.0%). Over the last 4 years revenue compounded at 6.1% a year. — as of 5 August 2026.
What is Leonardo DRS, Inc.'s profit?
Leonardo DRS, Inc. earned $0.1 B of net profit in the Mar 26 quarter, +28.6% year on year — the 7th straight quarter of growth. Full-year FY25 profit was $0.4 B. The operating margin ran 9.4% in the latest quarter. — as of 5 August 2026.
What is Leonardo DRS, Inc.'s market cap?
Leonardo DRS, Inc.'s market capitalisation is $12.0 B at a stock price of $45.3. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
Does Leonardo DRS, Inc. pay a dividend?
Yes — Leonardo DRS, Inc. declared $0.09 per share for Mar 26, and $0.36 per share across the last four reported quarters. — as of 5 August 2026.
What is Leonardo DRS, Inc.'s dividend per share?
Leonardo DRS, Inc.'s most recently declared dividend is $0.09 per share for Mar 26, giving $0.36 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.
What is Leonardo DRS, Inc.'s dividend yield?
Leonardo DRS, Inc.'s trailing dividend yield is 0.80%: $0.36 declared per share across the last four reported quarters, against a share price of $45.3. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 5 August 2026.
Is Leonardo DRS, Inc. growing?
Yes — Leonardo DRS, Inc. is growing: latest-quarter revenue +6.3% year on year, profit +28.6%, and the margin +1.9 pp at 9.4%. The 4-year compound rates are 6.1% (revenue) and 27.0% (profit). The earnings engine currently reads: improving — as of 5 August 2026.
How is Leonardo DRS, Inc. performing?
Leonardo DRS, Inc. is in a confirmed uptrend, 14 weeks in. Its latest quarter's revenue rose 6.3% and profit rose 28.6% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 3 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is Leonardo DRS, Inc. in?
Mixed — the growth curves are steadily positive, but ROCE at 11.1% is below the 15% bar this page requires to call it Consistent. The read comes from the last 12 quarters of growth (revenue growth +10.8% latest, profit growth +65.4% latest, eps growth +23.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is Leonardo DRS, Inc. in an uptrend?
Yes — the price is in a confirmed uptrend (week 14 of stage 2), trading +9.2% versus its 200-day average and at 78% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is Leonardo DRS, Inc. beating the market?
On recent form, yes — Leonardo DRS, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 3 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 3.7 years the stock moved +366% against the S&P 500's +90% — ahead of the index over the full window. — as of 5 August 2026.
Will Leonardo DRS, Inc.'s stock price go up?
This page publishes no price forecast for Leonardo DRS, Inc. What it measures instead: the stock price is $45.3, the price is in a confirmed uptrend 14 weeks in. Direction is not something this site claims to know. — as of 5 August 2026.
Is the market betting against Leonardo DRS, Inc.?
Somewhat — short interest is 3.8% of Leonardo DRS, Inc.'s tradable float, about 2.3 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does Leonardo DRS, Inc. have too much debt?
No — Leonardo DRS, Inc.'s debt-to-equity is 0.10. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. The returns on this page are earned, not borrowed — as of 5 August 2026.
What is Leonardo DRS, Inc.'s capex?
Leonardo DRS, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.1 B. — as of 5 August 2026.
What is Leonardo DRS, Inc.'s cash flow?
Leonardo DRS, Inc. generated $0.4 B of operating cash flow in FY25 and $0.2 B of free cash flow after $0.1 B of capital spending. Reported profit that year was $0.4 B, so operating cash ran behind profit. — as of 5 August 2026.
Is Leonardo DRS, Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 90% of Leonardo DRS, Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $0.4 B against reported profit of $0.4 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is Leonardo DRS, Inc.?
On the balance sheet, the Z-score reads 5.55 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.
Where is Leonardo DRS, Inc. in its business cycle?
Leonardo DRS, Inc.'s FY25 operating margin was 9.6%, against a 5-year band of 8.1%–20.8%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 9.4%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Leonardo DRS, Inc. story?
Biggest watch item: the price is already 14 weeks into its uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Leonardo DRS, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Leonardo DRS, Inc.'s earnings have outrun its stock. EPS grew +28.7% in a year against a +8.6% price move. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.